Department of Ophthalmology at St. Franziskus Hospital, Muenster, Hohenzollernring 74, 48145, Muenster, Germany.
University of Duisburg-Essen, Duisburg, Germany.
Arthritis Res Ther. 2020 Apr 15;22(1):81. doi: 10.1186/s13075-020-02166-3.
To analyze whether ANA-positive idiopathic anterior uveitis differs from JIA-associated uveitis concerning clinical course, response to treatment, and disease outcome.
Prospective study of the National Paediatric Rheumatological Database (NPRD) including its uveitis add-on module from the years 2002 to 2016. Cross-sectional data from the years 2002 to 2016 were analyzed. Patients with JIA-associated uveitis and with ANA-positive idiopathic anterior uveitis were included and the disease manifestation investigated in terms of uveitis characteristics and disease course.
Of the total cohort of 34,458 patients enrolled in the NPRD, including 3551 patients with uveitis, those with detailed uveitis documentation were taken into account: 62 ANA-positive patients with idiopathic anterior uveitis (group 1), 688 patients with initial uveitis diagnosis after JIA onset (group 2), and 61 JIA patients with initial uveitis diagnosis before arthritis onset (group 3). Anterior uveitis was documented in 100%, 94%, and 80% of patients and with insidious onset of uveitis flare in 50%, 70.9%, and 56.1% each in groups 1, 2, and 3, respectively. Use of topical or systemic corticosteroids and conventional synthetic or biological DMARDs did not significantly differ between the patient groups, either at the initial or the 2-year follow-up (2-FU) visits (mean 2 years, each p > 0.05). At 2-FU, uveitis inactivity was achieved in 64.7%, 55.8%, and 61.5% of patients in groups 1, 2, and 3 (p > 0.05). Uveitis-related complications were more frequent at the initial visit and at 2-FU in groups 1 and 3, as compared to group 2.
ANA-positive idiopathic uveitis and JIA-associated uveitis do not significantly differ concerning clinical course of uveitis, treatment, and response to corticosteroids and DMARDs.
分析抗核抗体阳性特发性前葡萄膜炎与幼年特发性关节炎相关性葡萄膜炎在临床病程、治疗反应和疾病结局方面是否存在差异。
这是一项对 2002 年至 2016 年期间国家儿科风湿病数据库（NPRD）及其葡萄膜炎附加模块的前瞻性研究。对 2002 年至 2016 年的横断面数据进行了分析。纳入了幼年特发性关节炎相关性葡萄膜炎和抗核抗体阳性特发性前葡萄膜炎患者，并根据葡萄膜炎特征和疾病过程对疾病表现进行了调查。
在纳入 NPRD 的 34458 名患者的总队列中，包括 3551 名患有葡萄膜炎的患者，对有详细葡萄膜炎记录的患者进行了考虑：62 名抗核抗体阳性特发性前葡萄膜炎患者（第 1 组），688 名幼年特发性关节炎发病后初次诊断为葡萄膜炎的患者（第 2 组），和 61 名幼年特发性关节炎发病前初次诊断为葡萄膜炎的患者（第 3 组）。第 1、2 和 3 组中分别有 100%、94%和 80%的患者存在前葡萄膜炎，分别有 50%、70.9%和 56.1%的患者存在葡萄膜炎发作的隐匿性起病。在初始或 2 年随访（FU）（平均 2 年，每组 p>0.05）时，各组患者之间在局部或全身皮质类固醇和常规合成或生物 DMARD 的使用上均无显著差异。在 2FU 时，第 1、2 和 3 组中分别有 64.7%、55.8%和 61.5%的患者达到葡萄膜炎无活动状态（p>0.05）。与第 2 组相比，第 1 组和第 3 组在初始就诊和 2FU 时更常发生葡萄膜炎相关并发症。
抗核抗体阳性特发性葡萄膜炎和幼年特发性关节炎相关性葡萄膜炎在葡萄膜炎的临床病程、治疗以及对皮质类固醇和 DMARDs 的反应方面没有显著差异。
